Does Semaglutide Cause Cancer? Review of Cancer Risk and Heart-Protective Benefits | Research

The takeaway

Human data remain reassuring that semaglutide does not significantly increase cancer risk, while its cardioprotective and anti-inflammatory properties may help protect the heart during cancer treatment.

No confirmed increase
Meta-analyses do not show significant increased risk of pancreatic cancer with semaglutide use in humans

What the researchers found

Human epidemiological data do not confirm the thyroid or pancreatic cancer risks seen in rodent models, and semaglutide's anti-inflammatory and cardioprotective properties may offer additional clinical value beyond metabolic control.

Why it matters

Millions of people take semaglutide for diabetes and obesity. Understanding its long-term cancer risk profile and potential heart-protective benefits is critical for informed prescribing and patient reassurance.

How the study worked

Narrative review analyzing clinical trial data, post-marketing surveillance reports, and meta-analyses on semaglutide's oncogenic potential and cardioprotective effects.

What this study cannot tell us

Narrative review without new primary data. Human exposure to semaglutide at scale is relatively recent, so long-term cancer risk may not be fully captured. The cardioprotective potential in cancer therapy contexts needs prospective validation.

How to read the evidence

Narrative review synthesizing clinical trials and meta-analyses. Reassuring but limited by relatively short human exposure history with GLP-1 drugs at population scale.

When this study was published

Published in 2025, reflecting the most current safety data available for semaglutide.

The bigger picture

GLP-1 receptor agonists are reshaping metabolic medicine. This review contributes to the evolving understanding of their safety profile and suggests these peptide drugs may have benefits that extend into oncology supportive care.

Questions still open

Should patients with family history of medullary thyroid carcinoma avoid GLP-1 receptor agonists entirely?
Could semaglutide be formally studied as a cardioprotective agent during chemotherapy?
How will the cancer risk profile evolve as millions more patients use semaglutide for longer durations?

Common questions

Does semaglutide cause thyroid cancer?

Animal studies showed thyroid tumors in rodents, but human data are reassuring. No significant increase in thyroid cancer has been confirmed in people. However, patients with genetic predisposition to medullary thyroid carcinoma should exercise caution.

Can semaglutide protect the heart during cancer treatment?

Emerging evidence suggests semaglutide has anti-inflammatory and cardioprotective properties that could help protect the heart from damage caused by certain cancer therapies, though this needs further study in clinical trials.

Read the original research

Clinical Impact of Semaglutide Beyond Glycemic Control: A Critical Analysis of Oncogenic Potential and Mitigation of Cardiotoxicity.

Pharmaceuticals (Basel, Switzerland), 19(2)

View on PubMed ↗Publisher’s paper ↗

Citation

Correra, Adriana; Mauriello, Alfredo; Cetoretta, Valeria; Maratea, Anna Chiara; Riegler, Lucia; Di Sarno, Isabella; Giallauria, Francesco; Guerra, Federico; Russo, Vincenzo; D'Andrea, Antonello. (2026). Clinical Impact of Semaglutide Beyond Glycemic Control: A Critical Analysis of Oncogenic Potential and Mitigation of Cardiotoxicity.. Pharmaceuticals (Basel, Switzerland), 19(2). https://doi.org/10.3390/ph19020297